 This is an open-label, mono-center phase III study designed to determine the maximum tolerated dose MTD and dose-limiting toxicities DLT of RAD001 in combination with carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer. Additionally, the study is designed to characterize the safety, the tolerability and efficacy of this study. 